Clinical trials: Urinary System Tumor
Metastatic Renal Cell Carcinoma
PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
This study will evaluate the safety of PD-1 knockout engineered T cells in treating metastatic advanced renal cancer. Blood samples will also be collected for research purposes.
- Trial name
- NCT02867332
- Testing
- PD-1 Knockout T Cells, Cyclophosphamide, IL-2
- Sponsor
- Peking University
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Clear Cell Renal Cell Carcinoma
Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC
This study is being conducted to test whether an imaging technique called a "piflufolastat F 18 PET/CT" imaging scan can be used to diagnose and describe the extent of clear cell Renal Carcinoma in patients.
- Trial name
- HARRIER (NCT07084909)
- Testing
- piflufolastat F 18
- Where
- 2 sites in United States
- Sponsor
- Lantheus Medical Imaging
Kidney Cancer
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00853021
- Testing
- aldesleukin, bevacizumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jorge A. Garcia, MD
Bladder Cancer
Urine-based Detection of Non-muscle Invasive Bladder
Non-muscle invasive bladder cancer (NMIBC), which comprises approximately 75% of bladder tumors, has the highest recurrence rate of all cancers, with around 70% of the patients developing local recurrences, despite elaborated…
- Trial name
- SOLUSION (NCT03962933)
- Where
- Denmark
- Volunteers
- 196 people
- Sponsor
- Nessn Azawi
Urinary Bladder Neoplasms
The Bladder Instillation Comparison Study
To compare the efficacy of Mitomycin C vs. Gemcitabine vs. no adjuvant treatment as a single intraoperative instillation in preventing recurrence of bladder cancer.
- Trial name
- BIC (NCT02695771)
- Testing
- Mitomycin C, Gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 101 people
- Sponsor
- Corewell Health West
Breast Cancer, Kidney Cancer
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Breast Cancer, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00365287
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Volunteers
- 148 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Neoplasms, Neoplasms, Glandular and Epithelial
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK)…
- Conditions
- Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms
- Trial name
- NCT02909452
- Testing
- Entinostat, Pembrolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
WAGR Syndrome, Wilm's Tumor
Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
This study will explore conditions caused by the absence of certain genes on chromosome 11. These conditions include WAGR syndrome, which is characterized by a kidney tumor called Wilm s tumor, aniridia (absence of the iris of…
- Conditions
- WAGR Syndrome, Wilm's Tumor, Aniridia, Urogenital Abnormalities
- Trial name
- NCT00758108
- Where
- United States
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Non-Muscle Invasive Bladder Neoplasms
Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use
The purpose of this pre-approval access program is to provide access to TAR-200 prior to its marketing authorization for the treatment of participant(s) with high-risk non-muscle invasive bladder cancer (HR-NMIBC).
- Trial name
- NCT06877676
- Testing
- TAR-200
- Sponsor
- Janssen Research & Development, LLC
Bladder Cancer
Improving Sensitivity of Urine Cytology for Bladder Cancer
Can a commercially available vibrating chair increase the number of urothelial cells in a urine sample of healthy participants non-invasively? The investigators plan is participants will alternate 15 minutes of drinking eight…
- Trial name
- NCT01826097
- Testing
- La-Z-Boy Massage Chair Vibration Effect on Bladder Cancer Cell Concentration
- Where
- United States
- Sponsor
- Johns Hopkins University
Solid Tumors, Hematologic Malignancies
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
- Trial name
- NCT07195916
- Testing
- INCA036873
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 280 people
- Sponsor
- Incyte Corporation
Bladder Cancer
URO-BCG-4 : Bladder Tumors Immunotherapy
Evaluation of maintenance BCG immunotherapy (dose 27 mg) in superficial bladder tumors. Two randomized arms (every 3 or 6 months) will be studied for a population of 300 patients.
- Trial name
- NCT00213655
- Testing
- bladder tumor recurrence
- Where
- France
- Volunteers
- 146 people
- Sponsor
- University Hospital, Rouen
Bladder Cancer
Surgery and BCG in Treating Patients With Bladder Cancer
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00002990
- Testing
- BCG vaccine
- Where
- 40 sites in Austria, Belgium and 9 more
- Volunteers
- 1,288 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Kidney Cancer, Metastatic Cancer
Magnetic Resonance Imaging-guided Thermal Radiofrequencey Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases
RATIONALE: Radiofrequency ablation uses high-frequency electric current to heat and kill tumor cells. Magnetic resonance imaging-guided radiofrequency ablation may an effective treatment for primary kidney cancer, liver…
- Conditions
- Kidney Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00006255
- Testing
- radiofrequency ablation, thermal ablation therapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Case Comprehensive Cancer Center
Bladder Carcinoma
TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer
This pilot clinical trial studies how well TracelT hydrogel works in localizing bladder tumors in patients undergoing radiation therapy for bladder cancer.
- Trial name
- NCT03125226
- Testing
- Polyethylene Glycol Hydrogel
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Renal Cell Cancer
WIRE - Novel Treatments in Renal Cell Cancer
Evaluation of proof of mechanism with relation to ktrans and/or CD8 count when different IMPs are given as monotherapy or as combination therapy.
- Trial name
- WIRE (NCT03741426)
- Testing
- Olaparib, Cediranib, Volrustomig
- Where
- 7 sites in United Kingdom
- Volunteers
- 134 people
- Sponsor
- CCTU- Cancer Theme
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells.
- Conditions
- Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00002515
- Testing
- filgrastim, carboplatin, thiotepa
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Hematuria, Urothelial Carcinoma
Urine DNA Methylation Detection for Hematuria Evaluation
Background: Hematuria, a common symptom of urinary system diseases, can result from various causes including infection, stones, trauma, and tumors.
- Conditions
- Hematuria, Urothelial Carcinoma, Bladder Cancer, Ureter Cancer
- Trial name
- NCT06427993
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Changhai Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.